I like the way you put split the company to make a point of MNTA being undervalued. I am pretty skeptical of analysts, but I found this report on Google finance. It seem to be accurate, upbeat and reiterates what you have been saying. I figured MNTA investors could use a positive viewpoint after the stunning recent drop in MNTA.
Even using your own bearish numbers (in which NVS/MNTA attain just a 10-15% market share of Lovenox)
Do you still consider the American market for Lovenox at $2.7 Billion?? Considering what I'm reading pertaining to Sanofi Discount agreements I'd cut that estimate by around 25%.
That would make the American market in the area of $2.0 Billion, with Sandoz's current share in the high teens.
Market Data 
Markets 
AI
